ELDN MEXC RealStocks
Own real ELDN shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 17:52:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Eledon Pharmaceuticals, Inc. (ELDN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.46, with a market capitalization of $224.28M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.35 to $4.49. This page covers its latest market performance, valuation, price trends and company information.
$224.28M | |
$2.65 | |
$2.84 | |
$2.44 | |
$2.67 | |
448.77K | |
907.10K | |
-- | |
$4.49 | |
$1.35 | |
-- | |
-- |
Eledon Pharmaceuticals, Inc. (ELDN) is currently trading at $2.46 as of 2026-11-12 17:51:00, down 8.43% ($0.23) from the previous close of $2.67
During today's regular trading session, ELDN has traded between $2.45 and $2.84, with a trading volume of 448.77K shares. The current price is near the lower end of today's range.
Over the past seven days, Eledon Pharmaceuticals, Inc. (ELDN) moved from $2.62 to $2.46, representing a decline of 6.30% ($0.17).
The stock traded between $2.38 and $2.92 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 639.49 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 35.2%
ELDN is currently trading at $2.46, placing it 35.2% of the way from its 52-week low of $1.35 to its 52-week high of $4.49. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 33 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Eledon Pharmaceuticals, Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Eledon Pharmaceuticals, Inc. (ELDN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ELDN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ELDN shares and USD.
ELDN Shares to USD
1.00 ELDN shares = 2.455 USD
Calculations are estimates based on the latest available price and are for reference only.